CeleCor designs a randomized, placebo-controlled clinical trial to study zalunfiban or placebo, subcutaneously injected in STEMI patients treated in ambulances at the first point of contact. The primary endpoints were based on ECG and angiographic outcomes.

CeleCor modifies CeleBrate’s primary endpoints to a seven-point clinical scale and designates as a Phase 3 pivotal clinical trial after discussion with regulatory agencies.

Link to Clinical Trial

Positive results from the pivotal study presented during the American Heart Association’s Late-Breaking Sessions on Nov. 10, 2025. Study results published simultaneously in The New England Journal of Medicine Evidence.

Link to Press Release